• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five Forces Summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Technology o Market segments o Comparison by Technology placement o Cell and tissue-based - Market size and forecast 2019-2024 o Gene therapy - Market size and forecast 2019-2024 o Market opportunity by Technology • Customer landscape o Overview • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography • Drivers, Challenges, and Trends o Market drivers o Volume driver - Demand led growth o Volume driver - Supply led growth o Volume driver - External factors o Volume driver - Demand shift in adjacent markets o Price driver - Inflation o Price driver - Shift from lower to higher priced units o Market challenges o Market trends • Vendor Landscape o Overview o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Allergan Plc o Amgen Inc. o Hitachi Chemical Co. Ltd. o Integra LifeSciences Holdings Corp. o Medtronic Plc o MiMedx Group Inc. o Organogenesis Holdings Inc. o Smith & Nephew Plc o Takeda Pharmaceutical Co. Ltd. o Zimmer Biomet Holdings Inc. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations • Exhibits • 1.Key Finding 1 • 2.Key Finding 2 • 3.Key Finding 3 • 4.Key Finding 4 • 5.Key Finding 5 • 6.Key Finding 6 • 7.Key Finding 7 • 8.Market in focus • 9.Parent market • 10.Market characteristics • 11.Product / Service portfolio of key vendors included in the market definition • 12.Market segments • 13.Global - Market size and forecast 2019 - 2024 ($ million) • 14.Global market: Year-over-year growth 2019 - 2024 (%) • 15.Five forces analysis 2019 & 2024 • 16.Bargaining power of buyers • 17.Bargaining power of suppliers • 18.Threat of new entrants • 19.Threat of substitutes • 20.Threat of rivalry • 21.Market condition - Five forces 2019 • 22.Technology placement - Market share 2019-2024 (%) • 23.Comparison by Technology placement • 24.Cell and tissue-based - Market size and forecast 2019-2024 ($ million) • 25.Cell and tissue-based - Year-over-year growth 2019-2024 (%) • 26.Gene therapy - Market size and forecast 2019-2024 ($ million) • 27.Gene therapy - Year-over-year growth 2019-2024 (%) • 28. Market opportunity by Technology • 29.Customer landscape • 30.Market share by geography 2019-2024 (%) • 31.Geographic comparison • 32.North America - Market size and forecast 2019-2024 ($ million) • 33.North America - Year-over-year growth 2019-2024 (%) • 34.Europe - Market size and forecast 2019-2024 ($ million) • 35.Europe - Year-over-year growth 2019-2024 (%) • 36.Asia - Market size and forecast 2019-2024 ($ million) • 37.Asia - Year-over-year growth 2019-2024 (%) • 38.ROW - Market size and forecast 2019-2024 ($ million) • 39.ROW - Year-over-year growth 2019-2024 (%) • 40.Key leading countries • 41.Market opportunity by geography ($ million) • 42.Impact of drivers • 43.Impact of challenges • 44.Landscape disruption • 45.Industry risks • 46.Vendors covered • 47.Market positioning of vendors • 48.Allergan Plc - Overview (1/3) • 49.Allergan Plc - Overview (2/3) • 50.Allergan Plc - Overview (3/3) • 51.Allergan Plc - Business segments • 52.Allergan Plc - Key offerings • 53.Allergan Plc - Key customers • 54.Allergan Plc - Segment focus • 55.Amgen Inc. - Overview (1/3) • 56.Amgen Inc. - Overview (2/3) • 57.Amgen Inc. - Overview (3/3) • 58.Amgen Inc. - Business segments • 59.Amgen Inc. - Key offerings • 60.Amgen Inc. - Key customers • 61.Amgen Inc. - Segment focus • 62.Hitachi Chemical Co. Ltd. - Overview (1/3) • 63.Hitachi Chemical Co. Ltd. - Overview (2/3) • 64.Hitachi Chemical Co. Ltd. - Overview (3/3) • 65.Hitachi Chemical Co. Ltd. - Business segments • 66.Hitachi Chemical Co. Ltd. - Key offerings • 67.Hitachi Chemical Co. Ltd. - Key customers • 68.Hitachi Chemical Co. Ltd. - Segment focus • 69.Integra LifeSciences Holdings Corp. - Overview (1/3) • 70.Integra LifeSciences Holdings Corp. - Overview (2/3) • 71.Integra LifeSciences Holdings Corp. - Overview (3/3) • 72.Integra LifeSciences Holdings Corp. - Business segments • 73.Integra LifeSciences Holdings Corp. - Key offerings • 74.Integra LifeSciences Holdings Corp. - Key customers • 75.Integra LifeSciences Holdings Corp. - Segment focus • 76.Medtronic Plc - Overview (1/3) • 77.Medtronic Plc - Overview (2/3) • 78.Medtronic Plc - Overview (3/3) • 79.Medtronic Plc - Business segments • 80.Medtronic Plc - Key offerings • 81.Medtronic Plc - Key customers • 82.Medtronic Plc - Segment focus • 83.MiMedx Group Inc. - Overview (1/3) • 84.MiMedx Group Inc. - Overview (2/3) • 85.MiMedx Group Inc. - Overview (3/3) • 86.MiMedx Group Inc. - Product and service • 87.MiMedx Group Inc. - Key offerings • 88.MiMedx Group Inc. - Key customers • 89.MiMedx Group Inc. - Segment focus • 90.Organogenesis Holdings Inc. - Overview (1/3) • 91.Organogenesis Holdings Inc. - Overview (2/3) • 92.Organogenesis Holdings Inc. - Overview (3/3) • 93.Organogenesis Holdings Inc. - Business segments • 94.Organogenesis Holdings Inc. - Key offerings • 95.Organogenesis Holdings Inc. - Key customers • 96.Organogenesis Holdings Inc. - Segment focus • 97.Smith & Nephew Plc - Overview (1/3) • 98.Smith & Nephew Plc - Overview (2/3) • 99.Smith & Nephew Plc - Overview (3/3) • 100.Smith & Nephew Plc - Business segments • 101.Smith & Nephew Plc - Key offerings • 102.Smith & Nephew Plc - Key customers • 103.Smith & Nephew Plc - Segment focus • 104.Takeda Pharmaceutical Co. Ltd. - Overview (1/3) • 105.Takeda Pharmaceutical Co. Ltd. - Overview (2/3) • 106.Takeda Pharmaceutical Co. Ltd. - Overview (3/3) • 107.Takeda Pharmaceutical Co. Ltd. - Business segments • 108.Takeda Pharmaceutical Co. Ltd. - Key offerings • 109.Takeda Pharmaceutical Co. Ltd. - Key customers • 110.Takeda Pharmaceutical Co. Ltd. - Segment focus • 111.Zimmer Biomet Holdings Inc. - Overview (1/3) • 112.Zimmer Biomet Holdings Inc. - Overview (2/3) • 113.Zimmer Biomet Holdings Inc. - Overview (3/3) • 114.Zimmer Biomet Holdings Inc. - Product and service • 115.Zimmer Biomet Holdings Inc. - Key offerings • 116.Zimmer Biomet Holdings Inc. - Key customers • 117.Zimmer Biomet Holdings Inc. - Segment focus • 118.Currency conversion rates for US$ • 119.Research Methodology • 120.Validation techniques employed for market sizing • 121.Information sources • 122.List of abbreviations

Allergan Plc Amgen Inc. Hitachi Chemical Co. Ltd. Integra LifeSciences Holdings Corp. Medtronic Plc MiMedx Group Inc. Organogenesis Holdings Inc. Smith & Nephew Plc Takeda Pharmaceutical Co. Ltd. Zimmer Biomet Holdings Inc.